The Centers for Disease Control and Prevention (CDC) has recently updated its vaccine recommendations for three critical diseases: meningococcal, respiratory syncytial virus (RSV), and chikungunya.

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

US Advisory Committee on Immunization Practices recommends approval of GSK’s RSV vaccines, Arexvy for adults aged 50-59: London, UK Saturday, April 19, 2025, 09:00 Hrs [IST] GSK ...

As spring temperatures rise along with pollen counts in Georgia, the state is seeing a decline in winter respiratory ...

Colombia's health ministry yesterday declared a public health emergency owing to the circulation of yellow fever in several ...

US flu activity declined steadily again last week, with rates of influenza-like illness (ILI) dropping further and staying ...

The Advisory Committee on Immunization Practices convened to make expanded vaccine recommendations amidst CDC leadership changes.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

A HORRIFIED dad has spoken of how he has watched not one daughter, but both fight for their lives in hospital. “It turns out ...